N-Terminal Pro-B-Type Natriuretic Peptide and Risk of Future Cognitive Impairment in the REGARDS Cohort

What Was Tested

This observational study paper looks at BNP (Nesiritide).

To study the association of NT-proBNP with risk of incident cognitive impairment.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

The Reasons for Geographic and Racial Differences in Stroke is a national cohort study of 30,239 black and white Americans age 45 and older at baseline, enrolled in 2003-7.

Among participants without prebaseline stroke or cognitive impairment, baseline NT-proBNP was measured in 470 cases of incident cognitive impairment and 557 controls.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Cases were participants scoring below the 6th percentile of demographically-adjusted means on at least 2 of 3 serially administered tests (word list learning, word list recall and semantic fluency) over 3.5 years follow-up.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Black People, Case-Control Studies, Cognitive Dysfunction, Cohort Studies, Forecasting and Longitudinal Studies.

The authors tagged it with the keywords brain, cognition disorders, natriuretic peptide, prospective study and risk factors.

What This Means in Plain Language

The paper is a randomized study of BNP (Nesiritide).

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (Journal of Alzheimer's disease : JAD), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.